From Grok:
No, there are no FDA accelerated approvals granted based solely on a Phase 1 trial.
The FDA's Accelerated Approval pathway (established in 1992 and updated over time) allows earlier approval for drugs treating serious or life-threatening conditions with unmet needs, using surrogate endpoints (e.g., tumor response rates in oncology) or intermediate clinical endpoints reasonably likely to predict clinical benefit. However, this requires data from an "adequate and well-controlled" study—typically a pivotal trial showing meaningful effect on such an endpoint.
Key Reasons Why Pure Phase 1-Only Accelerated Approvals Do Not Occur
Phase 1 focus: These trials primarily assess safety, dosing, pharmacokinetics, and initial tolerability in small groups (often 20–100 participants, sometimes healthy volunteers or patients in oncology). They are not designed or powered to provide robust efficacy data on surrogate endpoints sufficient for approval.
Pivotal evidence requirement: Accelerated approvals rely on evidence from single-arm or randomized trials demonstrating durable responses or other surrogates. Historical examples (e.g., many oncology drugs) use Phase 2 data, expanded Phase 1/2 cohorts, or early Phase 3 signals—not standalone Phase 1.
Analyses of approvals: Studies of accelerated approvals (e.g., 2015–2022 data) show that ~22% of pre-approval pivotal trials supporting accelerated approvals were Phase 1 trials. However, these were not "Phase 1 only"—they involved Phase 1 expansions or combined Phase 1/2 designs where the efficacy signal came from larger patient cohorts treated at the recommended dose, often functioning as de facto pivotal data with response rates and duration of response. Even in those cases, the approval was not based exclusively on initial dose-escalation Phase 1 portions.
FDA guidance and practice: Recent oncology guidance prefers randomized controlled trials for accelerated approval, and single-arm trials (common historically) still need substantial, interpretable efficacy signals beyond basic safety. No official FDA documentation, approval lists, or analyses describe any case of accelerated approval from Phase 1 safety/dosing data alone without efficacy demonstration.
Closest Scenarios (But Not "Phase 1 Only"
Some modern accelerated approvals in oncology (e.g., certain bispecifics or targeted therapies) have included data from Phase 1 trials with strong, durable response rates in expansion cohorts.
Recent policy shifts (as of 2026) emphasize one high-quality pivotal trial (which could be early-phase in rare diseases) plus confirmatory evidence, but this still requires efficacy demonstration—not pure Phase 1 safety data.
Examples like Gleevec historically used Phase 2 data; more recent cases blend phases but never rely solely on standard Phase 1.
In summary, while accelerated approval can draw from early-phase data (especially in oncology or rare diseases with compelling signals), no drug has received accelerated approval based exclusively on a traditional Phase 1 trial without efficacy-supporting data from expanded cohorts or later phases. All accelerated approvals require evidence reasonably likely to predict benefit, which Phase 1 alone does not provide. For the most current list of accelerated approvals, check the FDA's Accelerated Approval Program page or Drugs@FDA database. If you're asking about a specific drug, therapeutic area, or recent example, provide details for more targeted info!
No, there are no FDA accelerated approvals granted based solely on a Phase 1 trial.
The FDA's Accelerated Approval pathway (established in 1992 and updated over time) allows earlier approval for drugs treating serious or life-threatening conditions with unmet needs, using surrogate endpoints (e.g., tumor response rates in oncology) or intermediate clinical endpoints reasonably likely to predict clinical benefit. However, this requires data from an "adequate and well-controlled" study—typically a pivotal trial showing meaningful effect on such an endpoint.
Key Reasons Why Pure Phase 1-Only Accelerated Approvals Do Not Occur
Phase 1 focus: These trials primarily assess safety, dosing, pharmacokinetics, and initial tolerability in small groups (often 20–100 participants, sometimes healthy volunteers or patients in oncology). They are not designed or powered to provide robust efficacy data on surrogate endpoints sufficient for approval.
Pivotal evidence requirement: Accelerated approvals rely on evidence from single-arm or randomized trials demonstrating durable responses or other surrogates. Historical examples (e.g., many oncology drugs) use Phase 2 data, expanded Phase 1/2 cohorts, or early Phase 3 signals—not standalone Phase 1.
Analyses of approvals: Studies of accelerated approvals (e.g., 2015–2022 data) show that ~22% of pre-approval pivotal trials supporting accelerated approvals were Phase 1 trials. However, these were not "Phase 1 only"—they involved Phase 1 expansions or combined Phase 1/2 designs where the efficacy signal came from larger patient cohorts treated at the recommended dose, often functioning as de facto pivotal data with response rates and duration of response. Even in those cases, the approval was not based exclusively on initial dose-escalation Phase 1 portions.
FDA guidance and practice: Recent oncology guidance prefers randomized controlled trials for accelerated approval, and single-arm trials (common historically) still need substantial, interpretable efficacy signals beyond basic safety. No official FDA documentation, approval lists, or analyses describe any case of accelerated approval from Phase 1 safety/dosing data alone without efficacy demonstration.
Closest Scenarios (But Not "Phase 1 Only"
Some modern accelerated approvals in oncology (e.g., certain bispecifics or targeted therapies) have included data from Phase 1 trials with strong, durable response rates in expansion cohorts.
Recent policy shifts (as of 2026) emphasize one high-quality pivotal trial (which could be early-phase in rare diseases) plus confirmatory evidence, but this still requires efficacy demonstration—not pure Phase 1 safety data.
Examples like Gleevec historically used Phase 2 data; more recent cases blend phases but never rely solely on standard Phase 1.
In summary, while accelerated approval can draw from early-phase data (especially in oncology or rare diseases with compelling signals), no drug has received accelerated approval based exclusively on a traditional Phase 1 trial without efficacy-supporting data from expanded cohorts or later phases. All accelerated approvals require evidence reasonably likely to predict benefit, which Phase 1 alone does not provide. For the most current list of accelerated approvals, check the FDA's Accelerated Approval Program page or Drugs@FDA database. If you're asking about a specific drug, therapeutic area, or recent example, provide details for more targeted info!
2
